Interius BioTherapeutics has entered into a definitive agreement to be acquired by Kite Pharma, a Gilead company.

Congratulations to Pennovation Works Lab company Interius BioTherapeutics on the announcement of their acquisition!

Kite Pharma, a Gilead Sciences company, announced that it has entered into a definitive agreement to acquire biotechnology company Interius BioTherapeutics for $350 million.

Congratulations to the Interius team and all involved in the agreement!

Read the press release: https://bwnews.pr/4oO5Xjn